Tranexamic Acid Therapeutic Cheat Sheet
Tranexamic acid (TXA) is a synthetic lysine derivative that reversibly blocks the lysine-binding site on plasminogen, preventing conversion to plasmin. While originally developed as an antifibrinolytic agent to reduce bleeding, TXA has several downstream effects that make it useful in dermatology, particularly for pigmentary disorders, with emerging evidence in inflammatory disorders as well. TX …
Tranexamic acid (TXA) is a synthetic lysine derivative that reversibly blocks the lysine-binding site on plasminogen, preventing conversion to plasmin. While originally developed as an antifibrinolytic agent to reduce bleeding, TXA has several downstream effects that make it useful in dermatology, particularly for pigmentary disorders, with emerging evidence in inflammatory disorders as well. TX … 
Underrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation.
I interviewed author Jared Jagdeo, MD, MS, associat … 
Genetic disorders of pigmentation can affect more than just the skin, hair and nails, according to Dr. Nada Elbuluk, founder and director of the USC Skin of Color Center and Pigmentary Disorders Clinic. In an interview with Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, Dr. Elbuluk outlines three categories of genetic disorders of pigmentation and why an early an … 
A study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa … 
During the 2024 Pigmentary Disorders Exchange Symposium, expert dermatologists discussed and shed light on the evolving therapeutic landscape of pigmentary disorders. They addressed key advances, challenges, and gaps in current knowledge. The panel, which was moderated by Dr. Pearl Grimes, featured Dr. John Harris, Dr. Thierry Passeron, and Dr. Ariel Kauvar.
Dr. Harris kicked off the panel disc …